The UK became the first country in Europe to screen newborns for SMA in 2021, and among newly diagnosed UK Type 2/3 patients under 18, 65% now choose oral risdiplam over intrathecal nusinersen.
Spinal muscular atrophy is a motor neuron disease caused by SMN1 loss, with SMN2 copy number acting as the severity modifier. The UK added SMA to its national newborn screening programme in 2021, the first country in Europe to do so — screening via a day-5 heel-prick SMN1 homozygous-deletion PCR test, with positive results notified to Great Ormond Street Hospital or a regional SMA centre within 24–48 hours. Roughly 20–25 cases are detected through newborn screening annually, and pre-symptomatic treatment with gene therapy is now standard practice at 6 NHS-designated SMA gene therapy centres.
The living UK SMA cohort is estimated at around 1,000 patients across all types: roughly 200 with Type 1 (historically high mortality, now largely newborn-screening detected), 400 with Type 2 (the largest living cohort), 350 with Type 3, and 50 adult-onset Type 4. NHS Highly Specialised Services commission SMA management through four regional networks (Manchester, GOSH/Evelina, Birmingham/Alder Hey, and Edinburgh) — and all three approved therapies (onasemnogene abeparvovec/Zolgensma, risdiplam/Evrysdi, and nusinersen) are available on the NHS with confidential commercial arrangements. For newly diagnosed Type 2/3 patients under 18, a 2023 NHS centre survey found 65% of families choosing oral risdiplam over intrathecal nusinersen, reflecting a shift toward procedure-averse treatment preference.
UK spinal muscular atrophy population and therapy — by type, 2026
| SMA Type | Estimated UK Patients | Onset | Typical Diagnosis Route | Predominant NHS Therapy Pattern |
|---|---|---|---|---|
| Type 1 | ~200 | Infantile (historically <6 months) | Newborn screening (post-2021) or symptomatic | Pre-symptomatic gene therapy where NBS-detected |
| Type 2 | ~400 | Infantile/childhood | Symptomatic diagnosis (largest living cohort) | Oral risdiplam preferred in newly diagnosed <18 (65%) |
| Type 3 | ~350 | Childhood/juvenile | Symptomatic diagnosis | Oral risdiplam or nusinersen; family preference-driven |
| Type 4 | ~50 | Adulthood | Symptomatic diagnosis, often delayed | Nusinersen or risdiplam; smallest, least NBS-affected cohort |
Sources: NHS England SMA commissioning policy 2023; SMA UK patient organisation census 2023; NHS NBS Programme SMA expansion 2021; NICE HST15 (onasemnogene abeparvovec), TA755 (risdiplam), and TA588 (nusinersen) evidence submissions; NHS England SMA centre MDT survey 2023.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NBS pathway from heel-prick to SMA centre notification
- annual NBS-detected case volume
- the 6 designated NHS gene-therapy centres
- pre-symptomatic treatment standard of care
Delivers
- UK cohort sizing by SMA type
- four NHS regional SMA networks
- the 65%/35% risdiplam-vs-nusinersen split for newly diagnosed under-18s
- switch criteria across modalities
Delivers
- Older Type 2/3 adults with established disability outside gene-therapy eligibility
- NICE commercial-arrangement dynamics
- the shift in disease narrative from fatal to treatable
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How SMN1 loss causes motor neuron degeneration, with SMN2 copy number acting as the key severity modifier across SMA types
- Why this genetic mechanism underpins the UK's day-5 heel-prick SMN1 homozygous-deletion PCR screening test
- How the UK became the first European country to add SMA to national newborn screening in 2021, notifying GOSH or a regional centre within 24-48 hours
- Why roughly 20-25 cases are detected annually through newborn screening, feeding pre-symptomatic gene therapy at 6 NHS-designated centres
- How the living UK SMA cohort of roughly 1,000 patients splits across Type 1 (~200), Type 2 (~400), Type 3 (~350), and Type 4 (~50)
- How NHS Highly Specialised Services commission SMA management across four regional networks: Manchester, GOSH/Evelina, Birmingham/Alder Hey, and Edinburgh
- How all three approved therapies, onasemnogene abeparvovec, risdiplam, and nusinersen, are NHS-available under confidential commercial arrangements
- The NICE evidence base behind each therapy: HST15 (onasemnogene abeparvovec), TA755 (risdiplam), and TA588 (nusinersen)
- Why a 2023 NHS centre survey found 65% of newly diagnosed under-18 families choosing oral risdiplam over intrathecal nusinersen
- How this reflects a broader shift toward procedure-averse treatment preference in newly diagnosed Type 2/3 patients
- Why older Type 2/3 adults with established motor disability fall outside gene-therapy eligibility despite NICE-recommended access for younger patients
- How this population depends on chronic therapy choice (risdiplam or nusinersen) rather than the one-time gene-therapy option
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK spinal muscular atrophy disease landscape is built from primary NHS and NICE sources: NHS England SMA commissioning policy, NICE technology appraisal documentation for all three approved therapies, and the national newborn-screening programme specification — together with UK patient-organisation registry and survey data, not secondary summaries or unverified estimates.
Key sources: NHS NBS Programme SMA expansion (2021); NICE HST15 (onasemnogene abeparvovec), TA755 (risdiplam), and TA588 (nusinersen) evidence submissions; NHS England SMA commissioning policy 2023; SMA UK patient organisation census 2023; NHS England SMA centre MDT survey 2023; SMA UK quality of life survey 2023.
- UK SMA cohort sizing by type verified against SMA UK patient organisation census 2023
- Newborn-screening pathway and timeline verified against NHS NBS Programme SMA expansion 2021 and NICE HST15 evidence submission
- NICE recommendation status for all three therapies verified against NICE HST15, TA755, and TA588 evidence submissions
- Therapy-choice split for newly diagnosed under-18s verified against NHS England SMA centre MDT survey 2023
Frequently asked questions
Commission this assessment
AXLRx UK Spinal Muscular Atrophy Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the UK SMA patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.